Vireo Growth (OTCMKTS:VREOD – Get Free Report) and Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Insider and Institutional Ownership
81.5% of Axsome Therapeutics shares are held by institutional investors. 3.8% of Vireo Growth shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations for Vireo Growth and Axsome Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vireo Growth | 1 | 0 | 0 | 0 | 1.00 |
| Axsome Therapeutics | 1 | 2 | 18 | 1 | 2.86 |
Valuation and Earnings
This table compares Vireo Growth and Axsome Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vireo Growth | $268.77 million | 1.68 | -$68.11 million | ($3.30) | -3.02 |
| Axsome Therapeutics | $638.50 million | 16.14 | -$183.17 million | ($3.75) | -52.47 |
Vireo Growth has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Vireo Growth, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Vireo Growth and Axsome Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vireo Growth | -23.37% | -19.76% | -7.15% |
| Axsome Therapeutics | -24.68% | -265.55% | -28.10% |
Risk and Volatility
Vireo Growth has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.
Summary
Axsome Therapeutics beats Vireo Growth on 8 of the 15 factors compared between the two stocks.
About Vireo Growth
Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Receive News & Ratings for Vireo Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vireo Growth and related companies with MarketBeat.com's FREE daily email newsletter.
